EL7.AI
StocksMedium•12 November 2026•
4 min read

PsiQuantum Expands AMD Partnership to Build Large-Scale Quantum Computing Infrastructure

Key Facts

1PsiQuantum and AMD announced an expanded partnership on November 12, 2026, to design large-scale, fault-tolerant quantum computing infrastructure.
2AMD plans to make an equity investment in PsiQuantum, without disclosing its value or timing.
3The companies identified drug discovery as an initial area of work, with early results from simulations of covalent inhibitors.
4The companies plan to present more details at the SC26 conference from November 15 to 20, 2026.
5AMD shares closed at $552.9 on November 11, 2026, before the partnership announcement.

PsiQuantum and AMD announced on November 12, 2026, that they had expanded their strategic partnership to design the computing infrastructure needed to run large-scale, fault-tolerant quantum computers, according to a PsiQuantum statement. The collaboration includes developing hybrid applications that combine quantum computing, high-performance computing and artificial intelligence. PsiQuantum said AMD also plans to make an equity investment in the company to reinforce its commitment to the partnership. The statement did not specify the investment’s value or timing, and did not say it had been completed. The announcement links an existing technical collaboration with a planned future financing, while the companies did not disclose the investment terms.

The partnership builds on earlier work with AMD Versal FPGA chips, which PsiQuantum selected for its quantum platform, according to the statement. The expanded collaboration adds AMD Instinct GPUs, AMD EPYC processors and AMD ROCm software. These technologies will be integrated with PsiQuantum’s silicon photonics platform as part of a computing infrastructure design. This brings processors, accelerators and software into a single collaboration to support the operation of large-scale quantum systems. The companies said the design also targets applications combining quantum computing, high-performance computing and artificial intelligence.

The companies identified drug discovery as an initial area of work and said simulations of covalent inhibitors had produced early results. These molecules are relevant to cancer drug discovery research, according to the PsiQuantum statement. The company plans to continue work on accelerated computing solutions for commercial applications in pharmaceutical research and drug discovery. The announcement gave no numerical measurements of the results or timetable for developing these applications. Describing them as early-stage keeps the announcement focused on preliminary simulation results and plans for further work.

On error correction, the statement said researchers from both companies had optimized PRISM, a machine-learning decoder, for low-latency execution on programmable accelerators. The work aims to support a design that the companies describe as combining speed and accuracy for real-time error correction in large-scale photonic quantum computers. It is part of the computing infrastructure design targeted by the partnership, alongside the hybrid applications workstream. The statement did not set a date for making the design available or publishing it. The companies plan to present more details about the partnership at the SC26 conference in Chicago from November 15 to 20, 2026.

PsiQuantum says its plan is based on photonic quantum computing and manufacturing Omega chips at GlobalFoundries in Malta, New York. The company is targeting utility-scale quantum computers in Chicago and Moreton Bay, Queensland. In 2024, it announced partnerships with the Australian government and the Queensland state government, as well as the state of Illinois and the city of Chicago, to support the construction of these systems. The company describes its mission as building useful, fault-tolerant quantum computers by combining photonic qubits with established semiconductor manufacturing processes. It also says its Omega platform integrates single-photon sources, superconducting detectors and a high-performance optical switch.

On funding, PsiQuantum said on October 8, 2026, that it had received a conditional commitment for a loan of up to $150 million from the U.S. Department of War’s Office of Strategic Capital. That announcement does not specify the value of the equity investment AMD plans to make in the company, as the partnership statement gave no terms or timing. Separately, on November 5, 2026, AMD announced a collaboration with IBM and Oak Ridge National Laboratory to evaluate architectures, software and workflows for hybrid quantum systems and error correction. The platform included IBM quantum computers and the Umbra high-performance computing system, and the initial announcement named the 120-qubit IBM Quantum Nighthawk. AMD said the platform supports the U.S. Department of Energy’s Quantum Genesis mission, which aims to advance toward a scientifically relevant quantum computer by 2028.

EL7 data showed AMD shares closed at $552.9 on November 11, 2026, the last listed trading session before the partnership announcement the following day. That reading is the previous session’s closing price, not a share-price move in response to the news. The companies are due to disclose more details about the collaboration at the SC26 conference in Chicago from November 15 to 20. The current announcement focuses on computing infrastructure design, drug discovery applications and error correction, alongside AMD’s planned investment. The statement did not give the investment’s value or timing.

Open on chart